Please assess the completion status of the following clinical trial:

Trial Title: Influence of Dexmedetomidine on a Closed-Loop Anesthesia System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male patients scheduled for a general anesthesia~Exclusion Criteria:~* age lower than 18 years~* allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine,or to a myorelaxant or to an excipient,~* hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,~* history of central nervous system disease,~* patients receiving a psychotropic treatment or an agonist-antagonist opiate,~* hypovolemic patients,~* patients receiving a cardio-vascular treatment,~* expected bleeding surgical procedure,~* simultaneous general and loco-regional anesthesia,~* severe hepatic insufficiency.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
- dexmedetomidine (Type: EXPERIMENTAL): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).